NCT05483933 2025-12-23Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersShattuck Labs, Inc.Phase 1 Completed86 enrolled 17 charts
NCT05261490 2024-11-19Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerPfizerPhase 1/2 Terminated10 enrolled 21 charts